Worth the paper they are printed on? Findings from an independent evaluation of the understandability of patient information leaflets for antiseizure medications.
anticonvulsants
comprehension
epilepsy
pamphlets
pregabalin
rufinamide
self-management
Journal
Epilepsia
ISSN: 1528-1167
Titre abrégé: Epilepsia
Pays: United States
ID NLM: 2983306R
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
21
04
2022
received:
16
03
2022
accepted:
10
05
2022
pubmed:
14
5
2022
medline:
12
8
2022
entrez:
13
5
2022
Statut:
ppublish
Résumé
The Patient Information Leaflet (PIL) is an authoritative document that all people with epilepsy in the EU receive when prescribed antiseizure medication (ASM). We undertook the first independent, comprehensive assessment to determine how understandable they are. Regulators state that when patients are asked comprehension questions about them, ≥80% should answer correctly. Also, recommended is that PILs have a maximum reading requirement of US grade 8. Study 1: We obtained 140 current ASM PILs written in English. "Readability" was assessed using four tests, with and without adjustment for influence of familiar, polysyllabic words. A total of 179 online materials on epilepsy were also assessed. Study 2: Two PILs from Study 1 were randomly selected (Pregabalin Focus; Inovelon) and shown to 35 people from the UK epilepsy population. Their comprehension was assessed. Study 3: To understand whether the student population provides an accessible alternative population for future examination of ASM PILs, Study 3 was completed, using the same methods as Study 2, except that participants were 262 UK university students. Study 1: No PIL had a reading level of grade 8. Median was grade 11. Adjusting for context, the PILs were still at grade 10.5. PILs for branded ASMs were most readable. PILs were no more readable than (unregulated) online materials. Study 2: Users struggled to comprehend the PILs' key messages. The eight questions asked about pregabalin were typically answered correctly by 54%. For Inovelon, it was 62%. Study 3: Most student participants comprehended the PILs' key messages. The questions about Inovelon were answered correctly by 90%; for pregabalin it was 86%. This is the first independent and comprehensive examination of ASM PILs. It found that PILs being used fail to meet recommendations and regulatory requirements and risk not being understandable to a substantial proportion of users. In finding that people from the epilepsy population differ markedly in comprehension of PILs compared to students, this study highlights the importance of completing user testing with the target population.
Identifiants
pubmed: 35560228
doi: 10.1111/epi.17299
pmc: PMC9544238
doi:
Substances chimiques
Anticonvulsants
0
Pregabalin
55JG375S6M
Types de publication
Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2130-2143Informations de copyright
© 2022 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.
Références
Res Social Adm Pharm. 2018 Feb;14(2):196-202
pubmed: 28285793
BMJ. 2006 Aug 26;333(7565):417
pubmed: 16908462
J Pediatr Pharmacol Ther. 2018 Sep-Oct;23(5):362-366
pubmed: 30429689
Epilepsia. 2022 Aug;63(8):2130-2143
pubmed: 35560228
Epilepsy Behav. 2009 Jan;14(1):134-40
pubmed: 18824131
J Pharm Technol. 2017 Aug;33(4):128-136
pubmed: 34860991
Seizure. 2009 Jul;18(6):434-9
pubmed: 19419887
Rev Saude Publica. 2015;49:4
pubmed: 25741660
Int J Clin Pharm. 2016 Aug;38(4):888-98
pubmed: 27107582
J Clin Epidemiol. 1990;43(6):543-9
pubmed: 2348207
Pharm World Sci. 2005 Feb;27(1):35-40
pubmed: 15861933
JAMA Surg. 2016 Sep 1;151(9):831-7
pubmed: 27144966
J Gen Intern Med. 2008 May;23(5):561-6
pubmed: 18335281
Ann Pharmacother. 2011 Apr;45(4):452-8
pubmed: 21427296
Epilepsy Behav. 2015 Mar;44:35-9
pubmed: 25601720
Seizure. 1999 Feb;8(1):35-7
pubmed: 10091846
Health Educ Behav. 2011 Aug;38(4):389-403
pubmed: 21490309
BMJ Open. 2019 Dec 16;9(12):e032551
pubmed: 31848168
Ann Pharmacother. 2002 Dec;36(12):1856-61
pubmed: 12452744
Drug Healthc Patient Saf. 2018 Mar 19;10:9-19
pubmed: 29593437
BMJ Open. 2019 Feb 5;9(2):e024582
pubmed: 30813117
Int J Clin Pharmacol Ther. 2010 Dec;48(12):781-90
pubmed: 21084033
J Clin Epidemiol. 1993 May;46(5):423-9
pubmed: 8501467
Health Expect. 2012 Sep;15(3):283-94
pubmed: 21332620
Pharm Pract (Granada). 2016 Apr-Jun;14(2):702
pubmed: 27382423
Epilepsia. 2020 Mar;61(3):528-538
pubmed: 32096225